Updated 2-6-21					
	MercyOne Northest Iowa, a Health Ministry of	Please follow the Financial Assistance Policy for MercyOne Northeast Iowa aligned with 501R guidelines as stated in COVID-19 Self-Pay Price			
	Trinity Health, presents the following COVID-19				
	(Corona Virus) test price information for consumers		nmunication https://www.mercyone.org/northeastiowa/for-		
	to consider the cost of testing in our facility(ies).	patients/billing-and-financial-information			
CPT/HCPCS Code	CPT Code Description	Consumer friendly description	Standard Price	Cash Price	
	COVID-19 Specimen collection, any source, nasal,	COVID-19 Specimen collection, any			
C9803	blood, saliva	source, nasal, blood, saliva	\$86	\$5	
	Molecular Diagnosticc Testing				
	CDC 2019 novel coronavirus (2019-ncov) real-time	CDC COVID-19 VIRUS DETECTION TEST			
U0001	rt-pcr diagnostic panel	KIT	\$135	\$8	
	2019-ncov coronavirus, sars-cov-2/2019-ncov	COVID-19 VIRUS DETECTION TEST (NON			
U0002	(covid-19), any technique, multiple types or	PCR)	\$193	\$11	
	Infectious agent detection by nucleic acid (DNA or	,	, ,		
	RNA); severe acute respiratory syndrome	00/45 40/45/40 557507/04/7507/5/			
07605	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19 VIRUS DETECTION TEST (BY	4400		
87635	[00,40,40]	PCR)	\$193	\$11	
	Infectious agent detection by nucleic acid (DNA or				
	RNA); severe acute respiratory syndrome				
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19, influenza A and B, VIRUS			
87636	[COVID-19]) and influenza virus types A and B,	DETECTION TEST (BY PCR)	\$392	\$23	
	Infectious agent detection by nucleic acid (DNA or		7	,	
	RNA); severe acute respiratory syndrome				
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19, influenza A and B,			
	[COVID-19]), influenza virus types A and B, and	Respiratory Syncytial VIRUS DETECTION			
87637	recairatery cynoutial virus multipley amplified	TEST (BY PCR)	\$392	\$23	
	Infectious agent detection by nucleic acid (DNA or				
	RNA); severe acute respiratory syndrome	COVID-19 VIRUS DETECTION TEST (BY			
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	PCR) High throughput, High Volume			
110003	[COVID-19]), amplified probe technique, making	, , , , , ,	¢275	(22	
U0003	2010 nCoV Coronavirus SARS CoV 2/2010 nCoV	analyzer	\$375	\$22	
	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV				
	(COVID-19), any technique, multiple types or	COVID-19 VIRUS DETECTION TEST (NON			
	subtypes (includes all targets), non-CDC, making use	PCR) High throughput, High Volume			
U0004	of high throughput technologies as described by	analyzer	\$375	\$22	

-		1		
	Infectious agent detection by nucleic acid (DNA or			
	RNA); severe acute respiratory syndrome			
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
	[COVID-19]), amplified probe technique, CDC or			
	non-CDC, making use of high throughput	Use of HIGH Throughput technology		
	technologies, completed within 2 calendar days	with COVID VIRUS Detection resulted		
U0005	from date and time of specimen collection. (List	within 48 hours	\$25	\$15
	Molecular Testing Panel Codes that include COVID-			\$0
	Infectious disease (bacterial or viral respiratory			
	tract infection), pathogen specific nucleic acid (DNA			
	or RNA), 22 targets including severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2),			
	qualitative RT-PCR, nasopharyngeal swab, each	BIOFIRE 2.1 Respiratory Viral Panel		
0202U	nathogen reported as detected or not detected	including COVID-19 (BY PCR)	\$1,146	\$688
	Infectious disease (bacterial or viral respiratory			
	tract infection), pathogen-specific nucleic acid (DNA			
	or RNA), 22 targets including severe acute			
	respiratory syndrome coronavirus 2 (SARS-CoV-2),			
	qualitative RT-PCR, nasopharyngeal swab, each	QIAstat-Dx Respiratory SARS-CoV-2		
0223U	nathogen reported as detected or not detected	Panel including COVID-19 (BY PCR)	\$1,146	\$688
	Infectious disease (bacterial or viral respiratory			
	tract infection) pathogen-specific DNA and RNA, 21			
	targets, including severe acute respiratory			
	syndrome coronavirus 2 (SARS-CoV-2), amplified			
	probe technique, including multiplex reverse	ePlex® Respiratory Pathogen Panel 2	4	4
0225U	transcription for RNA targets, each analyte reported	including COVID-19 (NON PCR)	\$1,146	\$688
	Infectious disease (viral respiratory tract infection),			
	pathogen-specific RNA, 3 targets (severe acute	Cepheid Xpert® Xpress Repiratory Viral		
	respiratory syndrome coronavirus 2 [SARS-CoV-2],	Panel including COVID-19, Infuenza A &		
0240U	influenza A, influenza B), upper respiratory	B (PCR)	\$392	\$235
02400	Infectious disease (viral respiratory tract infection),	B (FCN)	Ç392	7233
	pathogen-specific RNA, 4 targets (severe acute			
	respiratory syndrome coronavirus 2 [SARS-CoV-2],	Cepheid Xpert® Xpress Repiratory Viral		
	influenza A, influenza B, respiratory syncytial virus	Panel including COVID-19, Infuenza A &		
0241U	[RSV]), upper respiratory specimen, each pathogen	B, Respiratory Syncytial (PCR)	\$392	\$235
02410	reported as detected or not detected Antigen Testing Codes	b, respiratory syricytiai (i erry	7372	7233
	Antigen resum Codes			

	Infectious agent antigen detection by immunoassay			
	technique, (eg, enzyme immunoassay [EIA],			
	enzyme-linked immunosorbent assay [ELISA],			
	fluorescence immunoassay [FIA],			
	immunochemiluminometric assay [IMCA])	Corona Virus/COVID-19 Antigen testing	4	4
87426	qualitative or semiquantitative: severe acute	to detect virus	\$170	\$10
	Infectious agent antigen detection by immunoassay			
	technique, (eg, enzyme immunoassay [EIA],			
	enzyme-linked immunosorbent assay [ELISA],			
	fluorescence immunoassay [FIA],			
	immunochemiluminometric assay [IMCA])	Canana Vinua (COVID 10 Influence A 8 D		
07420	qualitative or semiquantitative; severe acute	Corona Virus/COVID-19, Influenza A & B	¢170	¢1.0
87428	respiratory syndrome coronavirus (eg. SARS-CoV.	Antigen testing to detect virus	\$170	\$10
	Infectious agent antigen detection by immunoassay			
	with direct optical (ie, visual) observation; severe	COVID-19 Antigen Test By Rapid Visual		
87811	acute respiratory syndrome coronavirus 2 (SARS-	Detection	\$62	\$3
	Antibody Testing Codes			
	Immunoassay for infectious agent antibody(ies),			
	qualitative or semiquantitative, single step method	COVID-19 VIRUS Antibody Detection		
	(eg, reagent strip); severe acute respiratory	Test, single step (prior Infection of		
36328	syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	COVID-19), presence or absence	\$170	\$10
30320	Antibody; severe acute respiratory syndrome	COVID-19 VIRUS Antibody Detection	ψ <u>1</u> , σ	Ψ10
0.67.60	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	Test, complex (prior Infection of COVID-	Ć1F0	ĊC
86769			\$158	\$9
	Severe acute respiratory syndrome coronavirus 2	COVID-19 VIRUS Antibody Quantitiative		
86413	(SARS-CoV-2) (Coronavirus disease [COVID-19])	Test, (prior Infection of COVID-19)	\$169	\$10
	Neutralizing antibody, severe acute respiratory	COVID-19 VIRUS Blocking Antibody Test,		
86408	syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	(immunoresponse to block future	\$158	\$9
	Neutralizing antibody, severe acute respiratory	COVID-19 VIRUS Blocking Antibody		
86409	syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	Quantitative Test, (immunoresponse to	\$395	\$23
	Antibody, severe acute respiratory syndrome	COVID-19 Antibody Test, performed by		•
0224U	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	Mount Sinai Laboratory	\$158	\$9
02240	Surrogate viral neutralization test (sVNT), severe	COVID-19 VIRUS Blocking Antibody Test,	7130	γ.
	acute respiratory syndrome coronavirus 2 (SARS-	(immunoresponse to block future		
	CoV-2) (Coronavirus disease [COVID-19]), ELISA,	infections of COVID-19), Presence or	,	
0226U	. Cov 2/ (coronavirus discase [covid-15]/, ELISA,	Threedons of COVID 131, Fresence of	\$159	\$9